Loewy Caroline M
SEC-identified person · CIK 1367451 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Effector Therapeutics, Inc. LWAC | Director | filed 2021 - 2024 |
| Cymabay Therapeutics, Inc. CYMA | Director | filed 2016 - 2024 |
| Phoenix Biotech Acquisition Corp. PBAX | Director | filed 2021 - 2024 |
| Phasebio Pharmaceuticals Inc PHAS | Director | filed 2018 - 2023 |
| Aptose Biosciences Inc. APTO | Director | filed 2018 - 2022 |
| Zogenix, INC. ZGNX | Director | filed 2020 - 2022 |
| Corcept Therapeutics INC CORT | Chief Financial Officer | filed 2008 - 2008 |
| Poniard Pharmaceuticals, INC. PARD | EVP, Planning & IR | filed 2006 - 2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.